| Symbol | RVMDW |
|---|---|
| Name | REVOLUTION MEDICINES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 700 SAGINAW DRIVE, REDWOOD CITY, California, 94063, United States |
| Telephone | +1 650 481-6801 |
| Fax | — |
| — | |
| Website | https://www.revmed.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001628171 |
| Description | Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The companys products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. Additional info from NASDAQ: |
2026-07-07 13:24
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
Read more
2026-07-07 13:23
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
Read more
2026-07-02 12:00
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Read more
2026-07-02 12:00
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Read more
2026-07-01 22:25
Patel Sushil 🟡 adjusted position in 5.6K shares (1 derivative) of Revolution Medicines, Inc. (RVMD) at $192.61 ($1.3M) Transaction Date: Jun 29, 2026 | Filing ID: 000311
Read more
2026-06-29 20:44
📋 SUSHIL PATEL (Director) plans to sell 6K shares of Revolution Medicines, Inc. (at $182.08 each, total $1.0M) Filed: Jun 29, 2026 | ID: 006611
Read more
2026-06-24 23:31
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Read more
2026-06-24 23:31
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Read more
2026-06-24 20:35
📋 JACK ANDERS (Officer) plans to sell 20K shares of Revolution Medicines, Inc. (at $169.51 each, total $3.4M) Filed: Jun 24, 2026 | ID: 006461
Read more
2026-06-23 21:57
Kim Lorence H. 🟢 acquired 4.3K shares (1 derivative) of Revolution Medicines, Inc. (RVMD) at $162.99 Transaction Date: Jun 18, 2026 | Filing ID: 000290
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07573215 | Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metas… | — | PDAC | Available | — | — | ClinicalTrials.gov |
| NCT07621718 | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Inv… | Phase3 | Pancreatic Cancer | Recruiting | 2026-05-22 | 2030-04-22 | ClinicalTrials.gov |
| NCT07491445 | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patient… | Phase3 | Pancreatic Cancer | Recruiting | 2026-03-09 | 2029-03-01 | ClinicalTrials.gov |
| NCT07397338 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With So… | Phase1 | Advanced Solid Tumors | Recruiting | 2026-01-30 | 2029-05-01 | ClinicalTrials.gov |
| NCT07349537 | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | Phase1 | Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2026-01-08 | 2028-10-01 | ClinicalTrials.gov |
| NCT07252232 | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Ad… | Phase3 | Pancreatic Cancer | Recruiting | 2025-12-15 | 2030-07-10 | ClinicalTrials.gov |
| NCT06881784 | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 30… | Phase3 | NSCLC (Non-small Cell Lung Cancer) | Recruiting | 2025-05-06 | 2030-12-01 | ClinicalTrials.gov |
| NCT06625320 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Me… | Phase3 | Pancreatic Cancer | Active_Not_Recruiting | 2024-10-16 | 2027-12-01 | ClinicalTrials.gov |
| NCT06445062 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Phase1 | Colorectal Cancer | Recruiting | 2024-05-24 | 2027-07-15 | ClinicalTrials.gov |
| NCT06162221 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Phase1 | Non-Small Cell Lung Cancer, NSCLC | Recruiting | 2024-01-18 | 2028-12-01 | ClinicalTrials.gov |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy … | Phase1 | Non-Small Cell Lung Cancer (NSCLC) | Recruiting | 2023-11-14 | 2029-06-01 | ClinicalTrials.gov |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Phase1 | Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2023-09-07 | 2027-04-30 | ClinicalTrials.gov |
| NCT05557292 | RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma | Phase1 | Glioblastoma | Terminated | 2023-04-03 | 2025-12-31 | ClinicalTrials.gov |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects Wi… | Phase1 | Non-Small Cell Lung Cancer (NSCLC) | Active_Not_Recruiting | 2022-09-19 | 2027-09-30 | ClinicalTrials.gov |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mut… | Phase1 | Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2022-05-31 | 2027-07-26 | ClinicalTrials.gov |
| NCT05054725 | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mu… | Phase2 | Non-Small Cell Lung Cancer | Completed | 2021-12-30 | 2024-08-29 | ClinicalTrials.gov |
| NCT04774952 | Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors | Phase1 | Solid Tumors | Completed | 2021-04-07 | 2024-06-28 | ClinicalTrials.gov |
| NCT03989115 | Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi … | Phase1 | Solid Tumor | Completed | 2019-07-02 | 2022-02-08 | ClinicalTrials.gov |
| NCT03634982 | Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors | Phase1 | Solid Tumors | Unknown | 2018-09-28 | 2023-05-31 | ClinicalTrials.gov |
Total clinical trials: 19
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| cetuximab | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07349537 |
| daraxonrasib | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07349537 |
| RMC-5127 | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07349537 |
| daraxonrasib | Other | Preclinical | PDAC | AVAILABLE | NCT07573215 |
| Nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Gemcitabine (GEM) | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| 5-Fluorouracil | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Leucovorin (Calcium Folinate) | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Oxaliplatin | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Placebo | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Zoldonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| docetaxel | Other | Phase PHASE3 | NSCLC (Non-small Cell Lung Cancer) | RECRUITING | NCT06881784 |
| daraxonrasib | Other | Phase PHASE3 | NSCLC (Non-small Cell Lung Cancer) | RECRUITING | NCT06881784 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07252232 |
| RMC-9805 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| Pemetrexed | Other | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| Carboplatin | Other | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| Cisplatin | Other | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| Pembrolizumab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| RMC-6236 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| RMC-6291 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| Daraxonrasib (Cohort B1 only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| cetuximab (Cohort C2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Ivonescimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Zoldonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Elironrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| docetaxel | Other | Phase PHASE3 | NSCLC (Non-small Cell Lung Cancer) | RECRUITING | NCT06881784 |
| daraxonrasib | Other | Phase PHASE3 | NSCLC (Non-small Cell Lung Cancer) | RECRUITING | NCT06881784 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07252232 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| Nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Gemcitabine (GEM) | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| 5-Fluorouracil | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Leucovorin (Calcium Folinate) | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Oxaliplatin | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Placebo | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Zoldonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07252232 |
| RMC-6236 | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06040541 |
| RMC-9805 | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06040541 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| Oxaliplatin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| leucovorin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| 5-fluorouracil | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Liposomal irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| RMC-6236 | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| Nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Gemcitabine (GEM) | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| 5-Fluorouracil | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Leucovorin (Calcium Folinate) | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Oxaliplatin | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Placebo | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| Zoldonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07621718 |
| cetuximab | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07349537 |
| daraxonrasib | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07349537 |
| RMC-5127 | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07349537 |
| docetaxel | Other | Phase PHASE3 | NSCLC (Non-small Cell Lung Cancer) | RECRUITING | NCT06881784 |
| daraxonrasib | Other | Phase PHASE3 | NSCLC (Non-small Cell Lung Cancer) | RECRUITING | NCT06881784 |
| RMC-6236 | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05379985 |
| RMC-6291 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT05462717 |
| RMC-6236 | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05379985 |
| RMC-6291 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT05462717 |
| RMC-6236 | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05379985 |
| RMC-6291 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT05462717 |
| RMC-6236 | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05379985 |
| RMC-6291 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT05462717 |
| RMC-6236 | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05379985 |
| RMC-6291 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT05462717 |
| RMC-6236 | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05379985 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| RMC-6291 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT05462717 |
| RMC-6236 | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05379985 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| RMC-6291 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT05462717 |
| RMC-6236 | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05379985 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| RMC-6291 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT05462717 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| Daraxonrasib (Cohort B1 only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| cetuximab (Cohort C2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Ivonescimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Zoldonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Elironrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib (Cohort B1 only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| cetuximab (Cohort C2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Ivonescimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Zoldonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Elironrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib (Cohort B1 only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| cetuximab (Cohort C2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Ivonescimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Zoldonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Elironrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib (Cohort B1 only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| cetuximab (Cohort C2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Ivonescimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Zoldonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Elironrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib (Cohort B1 only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| cetuximab (Cohort C2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Ivonescimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Zoldonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Elironrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib (Cohort B1 only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| cetuximab (Cohort C2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Ivonescimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Zoldonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Elironrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| daraxonrasib | Other | Preclinical | PDAC | AVAILABLE | NCT07573215 |
| daraxonrasib | Other | Preclinical | PDAC | AVAILABLE | NCT07573215 |
| daraxonrasib | Other | Preclinical | PDAC | AVAILABLE | NCT07573215 |
| daraxonrasib | Other | Preclinical | PDAC | AVAILABLE | NCT07573215 |
| daraxonrasib | Other | Preclinical | PDAC | AVAILABLE | NCT07573215 |
| Daraxonrasib (Cohort B1 only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| cetuximab (Cohort C2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Ivonescimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Zoldonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Elironrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| RMC-5552 | Other | Phase PHASE1 | Glioblastoma | TERMINATED | NCT05557292 |
| Daraxonrasib (Cohort B1 only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| cetuximab (Cohort C2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Ivonescimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Zoldonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Elironrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| RMC-5552 | Other | Phase PHASE1 | Glioblastoma | TERMINATED | NCT05557292 |
| Daraxonrasib (Cohort B1 only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| cetuximab (Cohort C2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Ivonescimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Zoldonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Elironrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| RMC-5552 | Other | Phase PHASE1 | Glioblastoma | TERMINATED | NCT05557292 |
| Daraxonrasib (Cohort B1 only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| cetuximab (Cohort C2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Ivonescimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Zoldonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Elironrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| RMC-5552 | Other | Phase PHASE1 | Glioblastoma | TERMINATED | NCT05557292 |
| Daraxonrasib (Cohort B1 only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| cetuximab (Cohort C2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Ivonescimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Zoldonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Elironrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| RMC-5552 | Other | Phase PHASE1 | Glioblastoma | TERMINATED | NCT05557292 |
| Daraxonrasib (Cohort B1 only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| cetuximab (Cohort C2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Ivonescimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Zoldonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Elironrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| RMC-5552 | Other | Phase PHASE1 | Glioblastoma | TERMINATED | NCT05557292 |
| Daraxonrasib (Cohort B1 only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| cetuximab (Cohort C2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Ivonescimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Zoldonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Elironrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| RMC-5552 | Other | Phase PHASE1 | Glioblastoma | TERMINATED | NCT05557292 |
| Daraxonrasib (Cohort B1 only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| cetuximab (Cohort C2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Ivonescimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Zoldonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Elironrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| RMC-5552 | Other | Phase PHASE1 | Glioblastoma | TERMINATED | NCT05557292 |
| RMC-4630 | Other | Phase PHASE1 | Solid Tumors | UNKNOWN | NCT03634982 |
| Drug: Osimertinib | Drug | Phase PHASE1 | Solid Tumor | COMPLETED | NCT03989115 |
| Cobimetinib | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT03989115 |
| RMC-4630 | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT03989115 |
| RMC-5552 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT04774952 |
| RMC-6236 | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06040541 |
| RMC-9805 | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06040541 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07252232 |
| RMC-6236 | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05379985 |
| Sotorasib | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT05054725 |
| RMC-4630 | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT05054725 |
| cetuximab | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07349537 |
| daraxonrasib | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07349537 |
| RMC-5127 | Other | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07349537 |
| RMC-9805 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| Pemetrexed | Other | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| Carboplatin | Other | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| Cisplatin | Other | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| Pembrolizumab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| RMC-6236 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| RMC-6291 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| docetaxel | Other | Phase PHASE3 | NSCLC (Non-small Cell Lung Cancer) | RECRUITING | NCT06881784 |
| daraxonrasib | Other | Phase PHASE3 | NSCLC (Non-small Cell Lung Cancer) | RECRUITING | NCT06881784 |
| Daraxonrasib (Cohort B1 only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| cetuximab (Cohort C2 Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Ivonescimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Zoldonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Elironrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Daraxonrasib | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| RMC-9805 | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06445062 |
| nab-paclitaxel | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06445062 |
| gemcitabine | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06445062 |
| cetuximab | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06445062 |
| mFOLFIRINOX regimen | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06445062 |
| bevacizumab | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06445062 |
| mFOLFOX6 regimen | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06445062 |
| RMC-6236 | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06445062 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| RMC-6291 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT05462717 |
| RMC-5552 | Other | Phase PHASE1 | Glioblastoma | TERMINATED | NCT05557292 |
| Daraxonrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Elironrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07252232 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07252232 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07252232 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07252232 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07252232 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07252232 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07252232 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07252232 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07252232 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07252232 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07252232 |
| daraxonrasib | Other | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07252232 |
| Oxaliplatin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| leucovorin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| 5-fluorouracil | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Liposomal irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| RMC-6236 | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Oxaliplatin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| leucovorin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| 5-fluorouracil | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Liposomal irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| RMC-6236 | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Oxaliplatin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| leucovorin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| 5-fluorouracil | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Liposomal irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| RMC-6236 | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Oxaliplatin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| leucovorin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| 5-fluorouracil | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Liposomal irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| RMC-6236 | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Oxaliplatin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| leucovorin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| 5-fluorouracil | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Liposomal irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| RMC-6236 | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Oxaliplatin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| leucovorin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| 5-fluorouracil | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Liposomal irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| RMC-6236 | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Oxaliplatin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| leucovorin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| 5-fluorouracil | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Liposomal irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| RMC-6236 | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Oxaliplatin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| leucovorin | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| 5-fluorouracil | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Liposomal irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Irinotecan | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| nab-paclitaxel | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Gemcitabine | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| RMC-6236 | Other | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Daraxonrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Elironrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Daraxonrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Elironrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Daraxonrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Elironrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Daraxonrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Elironrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Daraxonrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Elironrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Daraxonrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Elironrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Daraxonrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Elironrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Daraxonrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Elironrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Daraxonrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Elironrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Daraxonrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Elironrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Daraxonrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Elironrasib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT06128551 |
| Daraxonrasib (Cohort B1 only) | DRUG | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | DRUG | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| cetuximab (Cohort C2 Only) | DRUG | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | DRUG | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Ivonescimab | DRUG | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Zoldonrasib | DRUG | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| RMC-5127 | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07349537 |
| docetaxel | DRUG | Phase PHASE3 | NSCLC (Non-small Cell Lung Cancer) | RECRUITING | NCT06881784 |
| daraxonrasib | DRUG | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| Oxaliplatin | DRUG | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| leucovorin | DRUG | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| 5-fluorouracil | DRUG | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Liposomal irinotecan | DRUG | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Irinotecan | DRUG | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Gemcitabine | DRUG | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| nab-paclitaxel | DRUG | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| gemcitabine | DRUG | Phase PHASE3 | Pancreatic Cancer | RECRUITING | NCT07491445 |
| cetuximab | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07349537 |
| mFOLFIRINOX regimen | DRUG | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06445062 |
| bevacizumab | DRUG | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06445062 |
| mFOLFOX6 regimen | DRUG | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06445062 |
| Pemetrexed | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| Carboplatin | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| Cisplatin | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| Pembrolizumab | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer, NSCLC | RECRUITING | NCT06162221 |
| Daraxonrasib | DRUG | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| Elironrasib | DRUG | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07397338 |
| RMC-9805 | DRUG | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06445062 |
| RMC-6291 | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT05462717 |
| RMC-6236 | DRUG | Phase PHASE3 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06625320 |
| Sotorasib | DRUG | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT05054725 |
| RMC-5552 | DRUG | Phase PHASE1 | Glioblastoma | RECRUITING | NCT05557292 |
| Drug: Osimertinib | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT03989115 |
| Cobimetinib | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT03989115 |
| RMC-4630 | DRUG | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT05054725 |
Total products: 421